Cytotoxicity Assays are developed to analyze the ability of certain drug compounds to destroy the healthy cells of an organism. Cytotoxic compounds can lead to accidental cell death (referred to as necrosis) or programmed cell death (referred to as apoptosis). During the nonclinical and clinical research phases of drug discovery and development, cytotoxicity assays assess the safety profile of the drug candidate. The method proves valuable in identifying off-target effects of certain drug compounds on the human body.
What is cytotoxicity: Cytotoxicity assays, also known as cell death assays, are used to measure the ability of certain drugs to damage or kill cells. Cytotoxic compounds can lead to accidental cell death (referred to as necrosis) or programmed cell death (referred to as apoptosis). During the nonclinical and clinical research phases of drug discovery and development, cytotoxicity assays assess the safety profile of the drug candidate.
In nonclinical research, cytotoxicity assays are used to evaluate the safety profile of the drug candidate. By destroying the healthy cells of an organism, this method proves valuable in identifying off-target effects of certain drug compounds on the human body. Drug compounds developed for cancer treatment need to be evaluated using cytotoxicity methods during various phases of testing activity.
Luminex multiplex assay service uses xMAP technology comprising a magnetic or non-magnetic bead-based flow cytometric platform. The Luminex system creates unique spectral addresses for the microspheres by labeling them as per the different ratios of red and far-red fluorophores. The Luminex system uses xMAP technology comprising a magnetic or non-magnetic bead-based flow cytometric platform. This technology allows multiple analytes (ex. cytokines, chemokines, metabolic biomarkers, etc.) to be quantitated simultaneously in a single biological matrix sample. Luminex xMAP technology is a bead-based flow cytometry platform that allows multiple analytes to be quantitated simultaneously in a single biological matrix sample. Luminex assay includes a broad range of analytes and was one of the first multiplex assays offering high throughput biomarker testing with reduced sample volume and reagent costs.
Luminex assay is a bead-based immunoassay multiplex technique that allows multiple analytes (ex. cytokines, chemokines, metabolic biomarkers, etc.) to be quantitated simultaneously in a single biological matrix sample. The results obtained using a standardized Luminex assay are superior or equivalent to conventional ELISA, even as the differentiated xMAP technology allows high throughput biomarker testing with reduced sample volume, test preparation and reagent costs.
Luminex multiplex assays are a bead-based flow cytometry method that allows simultaneous detection of multiple analytes (such as biomarkers, cytokines, and other blood cell proteins) in a single biological sample. A Luminex assay utilizes several “beads” to detect different analytes, resulting in a high throughput test that can be automated for clinical use.
The Luminex Cytokine Multiplex Kit is designed to simultaneously measure the levels of multiple cytokines (ex. IL-6, IL-8, TNF-α and CCL19) in a single sample in a highly sensitive and quantitative manner. This kit is an alternation of the standard Luminex 2 vial protocol and eliminates the need for two conjugate preparation steps. With one-step processing, data are easily obtained in as short as 4 hours.
Read More About Absbuzz.